NAMS — NewAmsterdam Pharma NV Income Statement
0.000.00%
Last trade - 00:00- $4.22bn
- $3.48bn
- $45.56m
- 57
- 14
- 98
- 58
Annual income statement for NewAmsterdam Pharma NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 103 | 14.1 | 45.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.19 | 35.9 | 106 | 197 | 222 |
| Operating Profit | -6.19 | -35.9 | -3.56 | -183 | -176 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.55 | -41.8 | -22.6 | -177 | -242 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.55 | -41.8 | -22.6 | -177 | -242 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.55 | -41.8 | -22.6 | -177 | -242 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.55 | -41.8 | -22.6 | -177 | -242 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.08 | -3.73 | -1.19 | -2.15 | -2.56 |
| Dividends per Share |